NCT01681212View on ClinicalTrials.gov

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Melanoma
Interventions
DRUG

Ipilimumab

DRUG

Dacarbazine

Trial Locations (6)

1040045

Local Institution, Chuo-ku

3908621

Local Institution, Matsumoto-shi

4093898

Local Institution, Chuo-shi

4118777

Local Institution, Sunto-gun

8128582

Local Institution, Fukuoka

8608556

Local Institution, Kumamoto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01681212 - Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter